If sufficient evidence for SOX7 can be obtained supporting a tumor suppressive role through functional studies, re-expression of silenced SOX7 through the administration of epi-drugs such as HDAC inhibitors [52] can be considered as a targeted therapy option for MM and allied neoplasms. Here, HDAC9 is linked to neoplasm.